Biomarkers, Not DSM, Needed To Speed Diagnostics, Drug Development For Brain Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
Diagnosing and treating brain disorders relies too much on subjective factors. But there are efforts brewing to turn that approach on its head, and move toward better biomarker-based diagnostics, according to the Broad Institute’s Steven Hyman, former head of the National Institute of Mental Health.